Who are Synthroid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): levothyroxin, Thyroxine, RESMETIROM, Tymlos, TERIPARATIDE, METHIMAZOLE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levothyroxine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Synthroid — Competitive Intelligence Brief

Synthroid (levothyroxine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone. Area: Oncology.

marketed Thyroid hormone THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial Oncology Small molecule (endogenous hormone replacement) Live · refreshed every 30 min

Target snapshot

Synthroid (levothyroxine) — Generic (originally multiple — AbbVie/Synthroid). Synthetic thyroxine (T4) that replaces deficient thyroid hormone, restoring normal metabolism, growth, and development.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Synthroid TARGET	levothyroxine	Generic (originally multiple — AbbVie/Synthroid)	marketed	Thyroid hormone	THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial	2002-08-13
levothyroxin	levothyroxin	Ain Shams University	marketed		THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial
Thyroxine	Thyroxine	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed		THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial
RESMETIROM	RESMETIROM		marketed	Thyroid Hormone Receptor beta Agonist [EPC]		2024-01-01
Tymlos	ABALOPARATIDE	Radius	marketed	Parathyroid Hormone-Related Peptide Analog [EPC]	Parathyroid hormone/parathyroid hormone-related peptide receptor	2017-01-01
TERIPARATIDE	TERIPARATIDE		marketed	Parathyroid Hormone Analog [EPC]		2002-01-01
METHIMAZOLE	METHIMAZOLE		marketed	Thyroid Hormone Synthesis Inhibitor [EPC]		1950-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone class)

Generic (originally multiple — AbbVie/Synthroid) · 1 drug in this class
Meir Medical Center · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
National Institute of Mental Health (NIMH) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Synthroid — Competitive Intelligence Brief. https://druglandscape.com/ci/levothyroxine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab